Bronchoscopic Microsampling is a Useful Complementary Diagnostic Tool for Detecting Lung Cancer

Lung Cancer

Volumn 72, Issue 1, 2011, Pages 32-38

  Yasuda, Hiroyuki ^a   Soejima, Kenzo ^a   Nakayama, Sohei ^a   Kawada, Ichiro ^a   Nakachi, Ichiro ^a   Yoda, Satoshi ^a   Satomi, Ryosuke ^a   Ikemura, Shinnosuke ^a   Terai, Hideki ^a   Sato, Takashi ^a   Watanabe, Hideo ^a   Naoki, Katsuhiko ^a   Hayashi, Yuichiro ^a   Ishizaka, Akitoshi ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Bronchoscopic microsampling; EGFR mutation; EML4 ALK; Epigenetics; Epithelial lining fluid; Lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; NUCLEIC ACID;

ADULT; AGED; ALK GENE; ARTICLE; BRONCHOSCOPIC MICROSAMPLING; BRONCHOSCOPY; CANCER DIAGNOSIS; CANCER STAGING; DNA METHYLATION; EML4 GENE; FEMALE; GENE; GENE FUSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ALVEOLUS EPITHELIUM; LUNG CANCER; LUNG NODULE; MAJOR CLINICAL STUDY; MALE; METHYLATION; PRIORITY JOURNAL; SERODIAGNOSIS;

AGED; AGED, 80 AND OVER; BIOPSY; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; CELL CYCLE PROTEINS; DNA METHYLATION; FEMALE; GENE FUSION; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MUTATION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY; SERINE ENDOPEPTIDASES;

EID: 79952193107     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.07.016     Document Type: Article

References (45)

1. Herbst R.S., Heymach J.V., Lippman S.M. Lung cancer. N Engl J Med 2008, 359:1367-1380.
2. Belinsky S.A. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004, 4:707-717.
3. Tsou J.A., Hagen J.A., Carpenter C.L., Laird-Offringa I.A. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 2002, 21:5450-5461.
4. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., Mardis E., Kupfer D., Wilson R., Kris M., Varmus H. EGF receptor gene mutations are common in lung cancers from " never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101:13306-13311.
5. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
6. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
7. Solomon B., Varella-Garcia M., Camidge D.R. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 2009, 4:1450-1454.
8. Wang Y.C., Hsu H.S., Chen T.P., Chen J.T. Molecular diagnostic markers for lung cancer in sputum and plasma. Ann N Y Acad Sci 2006, 1075:179-184.
9. Li R., Todd N.W., Qiu Q., Fan T., Zhao R.Y., Rodgers W.H., Fang H.B., Katz R.L., Stass S.A., Jiang F. Genetic deletions in sputum as diagnostic markers for early detection of stage I non-small cell lung cancer. Clin Cancer Res 2007, 13:482-487.
10. Belinsky S.A., Liechty K.C., Gentry F.D., Wolf H.J., Rogers J., Vu K., Haney J., Kennedy T.C., Hirsch F.R., Miller Y., Franklin W.A., Herman J.G., Baylin S.B., Bunn P.A., Byers T. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 2006, 66:3338-3344.
11. Schmiemann V., Bocking A., Kazimirek M., Onofre A.S., Gabbert H.E., Kappes R., Gerharz C.D., Grote H.J. Methylation assay for the diagnosis of lung cancer on bronchial aspirates: a cohort study. Clin Cancer Res 2005, 11:7728-7734.
12. Grote H.J., Schmiemann V., Geddert H., Rohr U.P., Kappes R., Gabbert H.E., Bocking A. Aberrant promoter methylation of p16(INK4a), RARB2 and SEMA3B in bronchial aspirates from patients with suspected lung cancer. Int J Cancer 2005, 116:720-725.
13. de Fraipont F., Moro-Sibilot D., Michelland S., Brambilla E., Brambilla C., Favrot M.C. Promoter methylation of genes in bronchial lavages: a marker for early diagnosis of primary and relapsing non-small cell lung cancer? Lung Cancer 2005, 50:199-209.
14. Kim H., Kwon Y.M., Kim J.S., Lee H., Park J.H., Shim Y.M., Han J., Park J., Kim D.H. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. J Clin Oncol 2004, 22:2363-2370.
15. Wang Y., Yu Z., Wang T., Zhang J., Hong L., Chen L. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. Lung Cancer 2007, 56:289-294.
16. Tan S.H., Ida H., Lau Q.C., Goh B.C., Chieng W.S., Loh M., Ito Y. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol Rep 2007, 18:1225-1230.
17. Fujiwara K., Fujimoto N., Tabata M., Nishii K., Matsuo K., Hotta K., Kozuki T., Aoe M., Kiura K., Ueoka H., Tanimoto M. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 2005, 11:1219-1225.
18. Bearzatto A., Conte D., Frattini M., Zaffaroni N., Andriani F., Balestra D., Tavecchio L., Daidone M.G., Sozzi G. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Clin Cancer Res 2002, 8:3782-3787.
19. Watanabe M., Ishizaka A., Ikeda E., Ohashi A., Kobayashi K. Contributions of bronchoscopic microsampling in the supplemental diagnosis of small peripheral lung carcinoma. Ann Thorac Surg 2003, 76:1668-1672. discussion 1673.
20. Ishizaka A., Watanabe M., Yamashita T., Ogawa Y., Koh H., Hasegawa N., Nakamura H., Asano K., Yamaguchi K., Kotani M., Kotani T., Morisaki H., Takeda J., Kobayashi K., Ogawa S. New bronchoscopic microsample probe to measure the biochemical constituents in epithelial lining fluid of patients with acute respiratory distress syndrome. Crit Care Med 2001, 29:896-898.
21. Yamazaki K., Ogura S., Ishizaka A., Oh-hara T., Nishimura M. Bronchoscopic microsampling method for measuring drug concentration in epithelial lining fluid. Am J Respir Crit Care Med 2003, 168:1304-1307.
22. Feng Q., Hawes S.E., Stern J.E., Wiens L., Lu H., Dong Z.M., Jordan C.D., Kiviat N.B., Vesselle H. DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 2008, 17:645-654.
23. Safar A.M., Spencer H., Su X., Coffey M., Cooney C.A., Ratnasinghe L.D., Hutchins L.F., Fan C.Y. Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin Cancer Res 2005, 11:4400-4405.
24. Virmani A.K., Tsou J.A., Siegmund K.D., Shen L.Y., Long T.I., Laird P.W., Gazdar A.F., Laird-Offringa I.A. Hierarchical clustering of lung cancer cell lines using DNA methylation markers. Cancer Epidemiol Biomarkers Prev 2002, 11:291-297.
25. Nagai Y., Miyazawa H., Huqun, Tanaka T., Udagawa K., Kato M., Fukuyama S., Yokote A., Kobayashi K., Kanazawa M., Hagiwara K. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005, 65:7276-7282.
26. Takeuchi K., Choi Y.L., Soda M., Inamura K., Togashi Y., Hatano S., Enomoto M., Takada S., Yamashita Y., Satoh Y., Okumura S., Nakagawa K., Ishikawa Y., Mano H. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008, 14:6618-6624.
27. Brock M.V., Hooker C.M., Ota-Machida E., Han Y., Guo M., Ames S., Glockner S., Piantadosi S., Gabrielson E., Pridham G., Pelosky K., Belinsky S.A., Yang S.C., Baylin S.B., Herman J.G. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008, 358:1118-1128.
28. Tsou J.A., Galler J.S., Siegmund K.D., Laird P.W., Turla S., Cozen W., Hagen J.A., Koss M.N., Laird-Offringa I.A. Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma. Mol Cancer 2007, 6:70.
29. Ulivi P., Zoli W., Calistri D., Fabbri F., Tesei A., Rosetti M., Mengozzi M., Amadori D. p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. J Cell Physiol 2006, 206:611-615.
30. Liu Y., Lan Q., Siegfried J.M., Luketich J.D., Keohavong P. Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. Neoplasia 2006, 8:46-51.
31. Zochbauer-Muller S., Fong K.M., Virmani A.K., Geradts J., Gazdar A.F., Minna J.D. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001, 61:249-255.
32. Belinsky S.A., Grimes M.J., Casas E., Stidley C.A., Franklin W.A., Bocklage T.J., Johnson D.H., Schiller J.H. Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum. Br J Cancer 2007, 96:1278-1283.
33. Belinsky S.A., Palmisano W.A., Gilliland F.D., Crooks L.A., Divine K.K., Winters S.A., Grimes M.J., Harms H.J., Tellez C.S., Smith T.M., Moots P.P., Lechner J.F., Stidley C.A., Crowell R.E. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002, 62:2370-2377.
34. Kawada I., Soejima K., Watanabe H., Nakachi I., Yasuda H., Naoki K., Kawamura M., Eguchi K., Kobayashi K., Ishizaka A. An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients. J Thorac Oncol 2008, 3:1096-1103.
35. Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.L., Li L.Y., Watkins C.L., Sellers M.V., Lowe E.S., Sun Y., Liao M.L., Osterlind K., Reck M., Armour A.A., Shepherd F.A., Lippman S.M., Douillard J.Y. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
36. Ciardiello F., Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008, 358:1160-1174.
37. Inamura K., Takeuchi K., Togashi Y., Nomura K., Ninomiya H., Okui M., Satoh Y., Okumura S., Nakagawa K., Soda M., Choi Y.L., Niki T., Mano H., Ishikawa Y. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008, 3:13-17.
38. Choi Y.L., Takeuchi K., Soda M., Inamura K., Togashi Y., Hatano S., Enomoto M., Hamada T., Haruta H., Watanabe H., Kurashina K., Hatanaka H., Ueno T., Takada S., Yamashita Y., Sugiyama Y., Ishikawa Y., Mano H. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 2008, 68:4971-4976.
39. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., Fujiwara S., Watanabe H., Kurashina K., Hatanaka H., Bando M., Ohno S., Ishikawa Y., Aburatani H., Niki T., Sohara Y., Sugiyama Y., Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
40. Potti A., Mukherjee S., Petersen R., Dressman H.K., Bild A., Koontz J., Kratzke R., Watson M.A., Kelley M., Ginsburg G.S., West M., Harpole D.H., Nevins J.R. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006, 355:570-580.
41. Potti A., Dressman H.K., Bild A., Riedel R.F., Chan G., Sayer R., Cragun J., Cottrill H., Kelley M.J., Petersen R., Harpole D., Marks J., Berchuck A., Ginsburg G.S., Febbo P., Lancaster J., Nevins J.R. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006, 12:1294-1300.
42. Meyerson M., Carbone D. Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. J Clin Oncol 2005, 23:3219-3226.
43. Beer D.G., Kardia S.L., Huang C.C., Giordano T.J., Levin A.M., Misek D.E., Lin L., Chen G., Gharib T.G., Thomas D.G., Lizyness M.L., Kuick R., Hayasaka S., Taylor J.M., Iannettoni M.D., Orringer M.B., Hanash S. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002, 8:816-824.
44. Bhattacharjee A., Richards W.G., Staunton J., Li C., Monti S., Vasa P., Ladd C., Beheshti J., Bueno R., Gillette M., Loda M., Weber G., Mark E.J., Lander E.S., Wong W., Johnson B.E., Golub T.R., Sugarbaker D.J., Meyerson M. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001, 98:13790-13795.
45. Maheswaran S., Sequist L.V., Nagrath S., Ulkus L., Brannigan B., Collura C.V., Inserra E., Diederichs S., Iafrate A.J., Bell D.W., Digumarthy S., Muzikansky A., Irimia D., Settleman J., Tompkins R.G., Lynch T.J., Toner M., Haber D.A. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008, 359:366-377.